Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer
(2023) In Current Opinion in Oncology 35(1). p.54-60- Abstract
Purpose of reviewSmall cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when surgery is not a treatment option anymore. Over several decades, only minimal changes have been made in the therapeutic armamentarium of ES-SCLC. Recently, however, several new therapeutic avenues were defined, thus renewing the hope for patients with this recalcitrant cancer. Here, we present an overview of the most current therapeutic advances in ES-SCLC focusing in particular on consolidative thoracic radiation therapy (cTRT) and chemo-immunotherapy.Recent findingsThe incorporation of... (More)
Purpose of reviewSmall cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when surgery is not a treatment option anymore. Over several decades, only minimal changes have been made in the therapeutic armamentarium of ES-SCLC. Recently, however, several new therapeutic avenues were defined, thus renewing the hope for patients with this recalcitrant cancer. Here, we present an overview of the most current therapeutic advances in ES-SCLC focusing in particular on consolidative thoracic radiation therapy (cTRT) and chemo-immunotherapy.Recent findingsThe incorporation of immunotherapy in the standard-of-care of ES-SCLC patients and the resulting outcomes are both a remarkable hallmark of progress and a disappointment. Indeed, chemo-immunotherapy with or without cTRT and prophylactic cranial irradiation contributes to longer survival outcomes with minimal toxicity rates in well selected and properly monitored patients. Nevertheless, the gain in overall survival is still modest relative to that seen in many other solid tumors.SummaryDespite the encouraging results, further clinical trials are needed to determine the efficacy and safety of these therapeutic approaches, and moreover, to identify new predictive biomarkers of response.
(Less)
- author
- Berta, Judit ; Rózsás, Anita ; Megyesfalvi, Zsolt ; Ostoros, Gyula and Döme, Balázs LU
- organization
- publishing date
- 2023-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- chemo-immunotherapy, consolidative thoracic radiation therapy, extensive-stage small cell lung cancer, lung cancer
- in
- Current Opinion in Oncology
- volume
- 35
- issue
- 1
- pages
- 7 pages
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:36420570
- scopus:85143645053
- ISSN
- 1040-8746
- DOI
- 10.1097/CCO.0000000000000911
- language
- English
- LU publication?
- yes
- additional info
- Funding Information: B.D. was supported by the Austrian Science Fund (FWF I3522, FWF I3977 and I4677). Z.M. and B.D. acknowledge funding from the Hungarian National Research, Development and Innovation Office (KH130356 and KKP126790 to BD; “2020-1.1.6-JÖVO” and TKP2021-EGA-33 to B.D. and Z.M.). Z.M. was supported by the UNKP-20-3 and UNKP-21-3 New National Excellence Program of the Ministry for Innovation and Technology of Hungary, and by the Hungarian Respiratory Society (MPA #2020). Publisher Copyright: © 2023 Lippincott Williams and Wilkins. All rights reserved.
- id
- bacac4b2-4b2b-4f1a-87b4-c7420891d35c
- date added to LUP
- 2024-01-11 14:29:44
- date last changed
- 2024-10-12 04:35:25
@article{bacac4b2-4b2b-4f1a-87b4-c7420891d35c,
abstract = {{<p>Purpose of reviewSmall cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when surgery is not a treatment option anymore. Over several decades, only minimal changes have been made in the therapeutic armamentarium of ES-SCLC. Recently, however, several new therapeutic avenues were defined, thus renewing the hope for patients with this recalcitrant cancer. Here, we present an overview of the most current therapeutic advances in ES-SCLC focusing in particular on consolidative thoracic radiation therapy (cTRT) and chemo-immunotherapy.Recent findingsThe incorporation of immunotherapy in the standard-of-care of ES-SCLC patients and the resulting outcomes are both a remarkable hallmark of progress and a disappointment. Indeed, chemo-immunotherapy with or without cTRT and prophylactic cranial irradiation contributes to longer survival outcomes with minimal toxicity rates in well selected and properly monitored patients. Nevertheless, the gain in overall survival is still modest relative to that seen in many other solid tumors.SummaryDespite the encouraging results, further clinical trials are needed to determine the efficacy and safety of these therapeutic approaches, and moreover, to identify new predictive biomarkers of response.</p>}},
author = {{Berta, Judit and Rózsás, Anita and Megyesfalvi, Zsolt and Ostoros, Gyula and Döme, Balázs}},
issn = {{1040-8746}},
keywords = {{chemo-immunotherapy; consolidative thoracic radiation therapy; extensive-stage small cell lung cancer; lung cancer}},
language = {{eng}},
month = {{01}},
number = {{1}},
pages = {{54--60}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Current Opinion in Oncology}},
title = {{Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer}},
url = {{http://dx.doi.org/10.1097/CCO.0000000000000911}},
doi = {{10.1097/CCO.0000000000000911}},
volume = {{35}},
year = {{2023}},
}